Cite
Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome Med. 2021;13(1):155doi: 10.1186/s13073-021-00969-w.
Sicklick, J. K., Kato, S., Okamura, R., Patel, H., Nikanjam, M., Fanta, P. T., Hahn, M. E., De, P., Williams, C., Guido, J., Solomon, B. M., McKay, R. R., Krie, A., Boles, S. G., Ross, J. S., Lee, J. J., Leyland-Jones, B., Lippman, S. M., & Kurzrock, R. (2021). Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome medicine, 13(1), 155. https://doi.org/10.1186/s13073-021-00969-w
Sicklick, Jason K, et al. "Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study." Genome medicine vol. 13,1 (2021): 155. doi: https://doi.org/10.1186/s13073-021-00969-w
Sicklick JK, Kato S, Okamura R, Patel H, Nikanjam M, Fanta PT, Hahn ME, De P, Williams C, Guido J, Solomon BM, McKay RR, Krie A, Boles SG, Ross JS, Lee JJ, Leyland-Jones B, Lippman SM, Kurzrock R. Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. Genome Med. 2021 Oct 04;13(1):155. doi: 10.1186/s13073-021-00969-w. PMID: 34607609; PMCID: PMC8491393.
Copy
Download .nbib